TuHURA Biosciences (NASDAQ:HURA) Rating Lowered to "Sell" at Wall Street Zen

Key Points

• Wall Street Zen downgraded TuHURA Biosciences (NASDAQ: HURA) from "hold" to "sell", though three analysts still rate the stock a Buy and MarketBeat shows a consensus of Moderate Buy with a $9 price target.
• Shares opened at $2.35 (up ~2.6%), trade in a 12‑month range of $0.41–$4.20, with a market cap of about $149.4 million and a negative P/E of -3.73, reflecting the company's unprofitable status.
• TuHURA posted an EPS miss last quarter of ($0.13) versus ($0.12) expected and analysts project -0.45 EPS for the year; institutional ownership remains low (~0.62%) despite some recent small fund purchases.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) was downgraded by investment analysts at Wall Street Zen from a "hold" rating to a "sell" rating in a research note issued to investors on Saturday.

HURA has been the subject of a number of other research reports. Rodman & Renshaw assumed coverage on shares of TuHURA Biosciences in a report on Wednesday, April 15th. They issued a "buy" rating for the company. Weiss Ratings reaffirmed a "sell (e+)" rating on shares of TuHURA Biosciences in a report on Tuesday. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price target on shares of TuHURA Biosciences in a report on Tuesday, February 3rd. Three equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the company's stock. Based on data from MarketBeat, TuHURA Biosciences has a consensus rating of "Moderate Buy" and a consensus price target of $9.00.

TuHURA Biosciences Trading Up 2.6%

Shares of NASDAQ:HURA opened at $2.35 on Friday. TuHURA Biosciences has a 12 month low of $0.41 and a 12 month high of $4.20. The company has a 50-day moving average price of $1.90 and a 200 day moving average price of $1.62. The company has a market cap of $149.41 million, a price-to-earnings ratio of -3.73 and a beta of -0.32.

TuHURA Biosciences (NASDAQ:HURA - Get Free Report) last announced its quarterly earnings results on Tuesday, March 31st. The company reported ($0.13) EPS for the quarter, missing analysts' consensus estimates of ($0.12) by ($0.01). As a group, equities analysts forecast that TuHURA Biosciences will post -0.45 EPS for the current year.

Institutional Trading of TuHURA Biosciences

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in HURA. Bank of America Corp DE purchased a new stake in TuHURA Biosciences in the 4th quarter worth about $59,000. Jane Street Group LLC purchased a new stake in TuHURA Biosciences in the 1st quarter worth about $69,000. Geode Capital Management LLC raised its position in TuHURA Biosciences by 111.4% in the 2nd quarter. Geode Capital Management LLC now owns 582,992 shares of the company's stock worth $1,300,000 after purchasing an additional 307,260 shares during the period. JPMorgan Chase & Co. purchased a new stake in TuHURA Biosciences in the 2nd quarter worth about $27,000. Finally, New York State Common Retirement Fund purchased a new stake in TuHURA Biosciences in the 2nd quarter worth about $97,000. 0.62% of the stock is owned by hedge funds and other institutional investors.

About TuHURA Biosciences

TuHURA Biosciences is a clinical‐stage biotechnology company focused on the discovery and development of novel therapeutics using high‐dimensional proteomics. The company's core mission is to translate complex protein signatures into actionable drug targets across a range of disease areas. By integrating proteomic data with advanced computational analytics, TuHURA aims to bridge the gap between molecular disease understanding and the development of first‐in‐class therapies.

At the heart of TuHURA's approach is its proprietary platform, which leverages multiplexed protein profiling to generate rich phenotypic maps of disease states.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.